MedTrace Logo

Panc CA Risk Model & Biomarker Testing In High-Risk Cohort

NCT05287347 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-05-25

No results posted yet for this study

Summary

The purpose of this study is to test a double screening strategy for pancreatic cancer, based on a model developed using patient medical records. Investigators would also like to test whether adding specific blood tests, can further help identify people who have a higher risk of pancreatic cancer than the general population, and would benefit from imaging in order to detect cancer early.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

DIAGNOSTIC_TEST

Blood Specimen

Blood samples will be collected from study participants at one time-point in the study, for the following: 1. tumor markers CEA and CA 19-9: 2 ml blood will be collected. 2. glycomics: 0.5 cc blood will be collected 3. ctDNA: 20 cc blood will be collected

Sponsors & Collaborators

Principal Investigators

  • Limor Appelbaum, MD · Beth Israel Deaconess Medical Center

Eligibility

Min Age
50 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-12-03
Completion
2024-12-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05287347 on ClinicalTrials.gov